A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
复制标题
DOI：
10.1007/s12020-017-1341-2
复制
发表时间：
2017-08
期刊：
影响因子：
3.7
通讯作者：
Malecki MT
中科院分区：
文献类型：
--
作者：
Hohendorff J;Szopa M;Skupien J;Kapusta M;Zapala B;Platek T;Mrozinska S;Parpan T;Glodzik W;Ludwig-Galezowska A;Kiec-Wilk B;Klupa T;Malecki MT
SGLT2抑制剂是一类用于治疗2型糖尿病(T2 DM)的新型口服降糖药。它们对青年成熟型糖尿病(MODY)的有效性尚不清楚。我们的目标是评估单剂量10 mg达格列酮对肝细胞核因子1α-MODY、葡萄糖激酶-MODY和2型糖尿病患者的疗效。我们检查了14名HNF1A-MODY、19名GCK-MODY和12名2型糖尿病患者。所有被研究的人在他们目前的糖尿病治疗基础上，早上只接受一次剂量为10 mg的达格列酮。为了评估达格列酮的疗效，我们分析了尿糖/肌酐比值和血清1，5-脱水葡萄糖醇(1，5-AG)水平的变化。只有4例患者在服用达帕利嗪前尿糖阳性(1例HNF1A-MODY，2例GCK-MODY，1例T2 DM)，而在使用SGLT-2抑制剂后，所有受试者都出现了糖尿。治疗后，三组患者的平均血糖/肌酐比值均有显著变化(分别为20.51 ± 12.08，23.19 ± 8.10，9.84 ± 6.68 /mmoy，p <； 0.001)。事后分析显示，2型糖尿病患者和每种单基因糖尿病患者对达帕利福秦的反应，平均血糖/肌酐比率变化有显著差异(HNF1-A和GCK MODY分别为p = 0.02p = 0.003和p = 0.003)，但两种MODY形式之间没有显著差异(p = 0.7231)。血清1，5-AG仅在T2 DM组有显著变化，为−6.57 ± 7.34 mg/ml(p = 0.04)。在GCK-和HNF1A-MODY患者中，单次服用SGLT-2抑制剂达帕格列酮可导致比T2 DM患者更高的血糖尿。对于这些形式的MODY，Flozins是否是一种有效的治疗选择需要长期的临床研究。
SGLT2 inhibitors are a new class of oral hypoglycemic agents used in type 2 diabetes (T2DM). Their effectiveness in maturity onset diabetes of the young (MODY) is unknown. We aimed to assess the response to a single dose of 10 mg dapagliflozin in patients with Hepatocyte Nuclear Factor 1 Alpha (HNF1A)-MODY, Glucokinase (GCK)-MODY, and type 2 diabetes. We examined 14 HNF1A-MODY, 19 GCK-MODY, and 12 type 2 diabetes patients. All studied individuals received a single morning dose of 10 mg of dapagliflozin added to their current therapy of diabetes. To assess the response to dapagliflozin we analyzed change in urinary glucose to creatinine ratio and serum 1,5-Anhydroglucitol (1,5-AG) level. There were only four patients with positive urine glucose before dapagliflozin administration (one with HNF1A-MODY, two with GCK-MODY, and one with T2DM), whereas after SGLT-2 inhibitor use, glycosuria occurred in all studied participants. Considerable changes in mean glucose to creatinine ratio after dapagliflozin administration were observed in all three groups (20.51 ± 12.08, 23.19 ± 8.10, and 9.84 ± 6.68 mmol/mmol for HNF1A-MODY, GCK-MODY, and T2DM, respectively, p < 0.001 for all comparisons). Post-hoc analysis revealed significant differences in mean glucose to creatinine ratio change between type 2 diabetes and each monogenic diabetes in response to dapagliflozin (p = 0.02, p = 0.003 for HNF1-A and GCK MODY, respectively), but not between the two MODY forms (p = 0.7231). Significant change in serum 1,5-AG was noticed only in T2DM and it was −6.57 ± 7.34 mg/ml (p = 0.04). A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in T2DM. Whether flozins are a valid therapeutic option in these forms of MODY requires long-term clinical studies.
登录
查看更多内容
影响因子：
16.2
作者：
Pruhova S;Dusatkova P;Neumann D;Hollay E;Cinek O;Lebl J;Sumnik Z
通讯作者：
Sumnik Z
影响因子：
16.2
作者：
Pal A;Farmer AJ;Dudley C;Selwood MP;Barrow BA;Klyne R;Grew JP;McCarthy MI;Gloyn AL;Owen KR
通讯作者：
Owen KR
影响因子：
3.7
作者：
Nowak N;Hohendorff J;Solecka I;Szopa M;Skupien J;Kiec-Wilk B;Mlynarski W;Malecki MT
通讯作者：
Malecki MT
影响因子：
8.2
作者：
Isomaa, B;Henricsson, M;Groop, L
通讯作者：
Groop, L
影响因子：
6.7
作者：
Komoroski, B.;Vachharajani, N.;Pfister, M.
通讯作者：
Pfister, M.